Pharming Grp Nv Leid (PHGUF) 0.2800 $PHGUF
Pharming Reports on Financial Results for the First Six Months of 2016
PR Newswire Europe - Thu Jul 28, 12:01AM CDT
LEIDEN, The Netherlands, July 28, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming Reports on Annual General Meeting of Shareholders Pharming's Board of Supervisory Directors Announce Paul Sekhri as New Chairman
PR Newswire Europe - Wed May 25, 12:00PM CDT
LEIDEN, The Netherlands, May 25, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming Group: Interim Report on Financial Results for Q1 2016
PR Newswire Europe - Wed May 18, 12:01AM CDT
LEIDEN, The Netherlands, May 18, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming Group Report on Preliminary Financial Results 2015
PR Newswire Europe - Thu Mar 10, 12:01AM CST
LEIDEN, The Netherlands, March 10, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming extends distribution agreement for RUCONEST with Cytobioteck SAS for Central and South America
M2 - Tue Feb 09, 4:51AM CST
Medical company Pharming Group NV (Amsterdam
HARM.AS) said on Monday that it has expanded its exclusive distribution agreement with Cytobioteck SAS for the former's RUCONEST for the treatment of acute attacks of Hereditary Angioedema (HAE) by adding countries in Central and South America.
Pancreatitis Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x5689/pancreatitis) has announced the addition of the "Pancreatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pancreatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatitis Overview - Therapeutics Development - Pipeline Products for Pancreatitis - Overview - Pipeline Products for Pancreatitis - Comparative Analysis - Pancreatitis - Therapeutics under Development by Companies - Pancreatitis - Therapeutics under Investigation by Universities/Institutes - Pancreatitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatitis - Products under Development by Companies - Pancreatitis - Products under Investigation by Universities/Institutes - Pancreatitis - Companies Involved in Therapeutics Development - Atox Bio Inc. - CalciMedica, Inc. - D-Pharm Ltd. - Dynavax Technologies Corporation - Generon (Shanghai) Corporation Ltd. - GlaxoSmithKline Plc - Pharming Group N.V. For more information visit http://www.researchandmarkets.com/research/6x...ncreatitis
DVAX: 15.50 (-0.31), GSK: 45.18 (+0.06)
Ischemia Reperfusion Injury Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s73kf/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Reperfusion Injury Overview - Therapeutics Development - Pipeline Products for Ischemia Reperfusion Injury - Overview - Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis - Ischemia Reperfusion Injury - Therapeutics under Development by Companies - Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes - Ischemia Reperfusion Injury - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia Reperfusion Injury - Products under Development by Companies - Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes - Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development - Alligator Bioscience AB - Angion Biomedica Corp. - Antipodean Pharmaceuticals, Inc. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Curatis Pharma GmbH - Enteris BioPharma, Inc. - Erimos Pharmaceuticals, LLC - Gilead Sciences, Inc. - Ischemix - Kowa Company, Ltd. - LG Life Science LTD. - Omeros Corporation - Opsona Therapeutics Limited - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. (Inactive) - Prothix BV - Trophos SA - Zealand Pharma A/S For more information visit http://www.researchandmarkets.com/research/9s73kf/ischemia
GILD: 81.24 (-0.55), OMER: 11.70 (+0.51)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 17.61 (-0.25), BCRX: 3.46 (+0.05), ISIS: 57.56 (-0.28), ARWR: 5.98 (-0.03), SHPG: 191.43 (-3.01), IBIO: 0.63 (unch), DYAX: 38.04 (-0.37)
Hemophilia A Therapeutics Pipeline Review 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rtzx4/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hemophilia A Overview - Therapeutics Development - Pipeline Products for Hemophilia A - Overview - Pipeline Products for Hemophilia A - Comparative Analysis - Hemophilia A - Therapeutics under Development by Companies - Hemophilia A - Therapeutics under Investigation by Universities/Institutes - Hemophilia A - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hemophilia A - Products under Development by Companies - Hemophilia A - Products under Investigation by Universities/Institutes - Hemophilia A - Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - Apitope International NV - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - CSL Limited - DBV Technologies S.A. - Dimension Therapeutics, Inc. - Dong-A Socio Group - Emergent BioSolutions Inc. - EpiVax, Inc. - Expression Therapeutics LLC - F. Hoffmann-La Roche Ltd. - Green Cross Corporation - Inbiopro Solutions Pvt. Ltd. - Lentigen Technology, Inc. - mAbxience S.A. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Selecta Biosciences, Inc. - SK Chemicals Co., Ltd. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/5r...mophilia_a
BMRN: 98.20 (+0.11), EBS: 32.85 (-0.93), PFE: 36.67 (-0.18), SGMO: 6.16 (-0.18), RBIO: (), DMTX: 7.26 (-0.18), NVO: 56.54 (+0.20), OPK: 9.89 (-0.06), ONCE: 55.39 (+1.40), AZN: 34.29 (+2.75), CBIO: 1.49 (unch), BXLT: 46.02 (-0.18)
Pharming Announces Completion of Patient Enrolment in Clinical Study of RUCONEST® for Prophylaxis of Hereditary Angioedema
PR Newswire Europe - Wed Jan 06, 12:01AM CST
LEIDEN, the Netherlands, January 6, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming awarded marketing authorisation in South Korea for RUCONEST for HAE
M2 - Mon Dec 21, 4:24AM CST
Medical company Pharming Group NV (Euronext Amsterdam HARM) disclosed on Friday the receipt of the marketing authorisation for RUCONEST (recombinant human C1 inhibitor) in South Korea through its Seoul based South Korean specialty pharma partner, Hyupjin Corporation.
Hemophilia B Therapeutics Pipeline Report H2 2015 - 19 Companies & 27 Drug Profiles
M2 - Tue Dec 15, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/2f4z4g/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - Catalyst Biosciences, Inc. - CSL Limited - Dimension Therapeutics, Inc. - Emergent BioSolutions Inc. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - RegenxBio Inc. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Spark Therapeutics, Inc. - uniQure N.V. Drug Profiles - albutrepenonacog alfa - ALN-AT3 - AMT-060 - AZ-10047130 - BAX-335 - BAY-1093884 - CB-2679d - CB-813d - Cell Therapy for Hemophilia B - coagulation factor IX (recombinant) - coagulation factor IX-Fc (recombinant), Fc fusion protein - coagulation factor VIIa (recombinant) - concizumab - CSL-689 - DTX-101 - Gene Therapy for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - LR-769 - MOD-5014 - MOD-9017 - nonacog beta pegol - PF-06741086 - SB-FIX - SPK-FIX - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/2f...mophilia_b
EBS: 32.85 (-0.93), PFE: 36.67 (-0.18), SGMO: 6.16 (-0.18), RBIO: (), DMTX: 7.26 (-0.18), NVO: 56.54 (+0.20), OPK: 9.89 (-0.06), ONCE: 55.39 (+1.40), AZN: 34.29 (+2.75), CBIO: 1.49 (unch), BXLT: 46.02 (-0.18)
Kidney Transplantation Therapeutics Pipeline Report 2015 - 25 Companies & 30 Drug Profiles
M2 - Mon Dec 14, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqgdxr/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - Catalyst Biosciences, Inc. - CSL Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Effimune SAS - GlaxoSmithKline Plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Mabtech Limited - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Limited - Pharming Group N.V. - Prolong Pharmaceuticals - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tiziana Life Sciences Plc - Zyrnat Biotherapeutics SL Drug Profiles - albumin (human) - AMY-101 - AS-2521780 - basiliximab biobetter - BB-3 - belimumab - bleselumab - BRN-1889 - C1 esterase inhibitor (human) - Cardiotrophin-1 - carfilzomib - CB-2782 - Cell Therapy for Kidney Transplantation - CFZ-533 - Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FR-104 - FX-06 - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - reparixin - Sanguinate - T-Cell Therapy for Kidney Transplant - ZY-11 For more information visit http://www.researchandmarkets.com/research/cqgdxr/kidney
SHPG: 191.43 (-3.01), CBIO: 1.49 (unch), ALXN: 130.40 (+0.62), GSK: 45.18 (+0.06), NVS: 82.08 (-0.81)
Fabry Disease Therapeutics Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8r98p/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Alexion Pharmaceuticals, Inc. - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Genz-682452 - GZ-402671 - lucerastat - migalastat hydrochloride - migalastat hydrochloride Enzyme Replacement Therapy Biobetter - MOSS-AGAL - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease - Recombinant Enzymes for Pompe, Fabry and Hunter Diseases For more information visit http://www.researchandmarkets.com/research/h8...ry_disease
ALXN: 130.40 (+0.62), IBIO: 0.63 (unch), FOLD: 6.80 (-0.33)
Pharming Reports on Extraordinary General Meeting of Shareholders
PR Newswire Europe - Wed Oct 28, 11:30AM CDT
LEIDEN, The Netherlands, October 28, 2015 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming Group NV Interim Report January - September 2015
PR Newswire Europe - Wed Oct 28, 1:01AM CDT
LEIDEN, The Netherlands, October 28, 2015 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
FDA Grants RUCONEST® (C1 Esterase Inhibitor [Recombinant]) Twelve-Year Reference Product Exclusivity
PR Newswire Europe - Thu Oct 08, 12:01AM CDT
LEIDEN, Netherlands and BRIDGEWATER, New Jersey, October 8, 2015 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Global Gaucher's Disease Pipeline Review, H2 2015 - 16 Companies & 20 Drug Profiles
M2 - Wed Oct 07, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmwnzs/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Amicus Therapeutics, Inc. - Bioorganic Research and Services S.A. - Biosidus S.A. - Dong-A Socio Group - Genzyme Corporation - greenovation Biotech GmbH - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Lixte Biotechnology Holdings, Inc. - Neuraltus Pharmaceuticals, Inc. - Okklo Life Sciences BV - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - The International Biotechnology Center (IBC) Generium - UAB Profarma Drug Profiles - afegostat tartrate ERT - ambroxol - AT-3375 - BNT-001 - Gluco-Cerebosidase - GZ-402671 - imiglucerase biosimilar - LB-201 - LB-205 - miglustat - NP-003 - OKL-1014 - PRX-112 - Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - taliglucerase alfa For more information visit http://www.researchandmarkets.com/research/hm...rs_disease
FOLD: 6.80 (-0.33)
Pharming to elect Robin Wright as CFO at EGM
M2 - Tue Sep 08, 3:02AM CDT
Medical products company Pharming Group NV (Amsterdam HARM.AS) reported on Tuesday that it plans to elect Robin Wright as its new chief financial officer (CFO) and member of the management board at an Extraordinary General Meeting (EGM) of shareholders to be held on 28 October 2015 at 14:00 CET.
Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 81.24 (-0.55), OMER: 11.70 (+0.51)
Pharming Reports on Financial Results for the First Six Months of 2016
PR Newswire Europe - Thu Jul 28, 12:01AM CDT
LEIDEN, The Netherlands, July 28, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming Reports on Annual General Meeting of Shareholders Pharming's Board of Supervisory Directors Announce Paul Sekhri as New Chairman
PR Newswire Europe - Wed May 25, 12:00PM CDT
LEIDEN, The Netherlands, May 25, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming Group: Interim Report on Financial Results for Q1 2016
PR Newswire Europe - Wed May 18, 12:01AM CDT
LEIDEN, The Netherlands, May 18, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming Group Report on Preliminary Financial Results 2015
PR Newswire Europe - Thu Mar 10, 12:01AM CST
LEIDEN, The Netherlands, March 10, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming extends distribution agreement for RUCONEST with Cytobioteck SAS for Central and South America
M2 - Tue Feb 09, 4:51AM CST
Medical company Pharming Group NV (Amsterdam
HARM.AS) said on Monday that it has expanded its exclusive distribution agreement with Cytobioteck SAS for the former's RUCONEST for the treatment of acute attacks of Hereditary Angioedema (HAE) by adding countries in Central and South America. Pancreatitis Pipeline Review, H2 2015
M2 - Tue Feb 02, 5:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x5689/pancreatitis) has announced the addition of the "Pancreatitis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pancreatitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pancreatitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Pancreatitis Overview - Therapeutics Development - Pipeline Products for Pancreatitis - Overview - Pipeline Products for Pancreatitis - Comparative Analysis - Pancreatitis - Therapeutics under Development by Companies - Pancreatitis - Therapeutics under Investigation by Universities/Institutes - Pancreatitis - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Pancreatitis - Products under Development by Companies - Pancreatitis - Products under Investigation by Universities/Institutes - Pancreatitis - Companies Involved in Therapeutics Development - Atox Bio Inc. - CalciMedica, Inc. - D-Pharm Ltd. - Dynavax Technologies Corporation - Generon (Shanghai) Corporation Ltd. - GlaxoSmithKline Plc - Pharming Group N.V. For more information visit http://www.researchandmarkets.com/research/6x...ncreatitis
DVAX: 15.50 (-0.31), GSK: 45.18 (+0.06)
Ischemia Reperfusion Injury Therapeutics Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s73kf/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Reperfusion Injury Overview - Therapeutics Development - Pipeline Products for Ischemia Reperfusion Injury - Overview - Pipeline Products for Ischemia Reperfusion Injury - Comparative Analysis - Ischemia Reperfusion Injury - Therapeutics under Development by Companies - Ischemia Reperfusion Injury - Therapeutics under Investigation by Universities/Institutes - Ischemia Reperfusion Injury - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia Reperfusion Injury - Products under Development by Companies - Ischemia Reperfusion Injury - Products under Investigation by Universities/Institutes - Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development - Alligator Bioscience AB - Angion Biomedica Corp. - Antipodean Pharmaceuticals, Inc. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Curatis Pharma GmbH - Enteris BioPharma, Inc. - Erimos Pharmaceuticals, LLC - Gilead Sciences, Inc. - Ischemix - Kowa Company, Ltd. - LG Life Science LTD. - Omeros Corporation - Opsona Therapeutics Limited - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. (Inactive) - Prothix BV - Trophos SA - Zealand Pharma A/S For more information visit http://www.researchandmarkets.com/research/9s73kf/ischemia
GILD: 81.24 (-0.55), OMER: 11.70 (+0.51)
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfx77x/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) Overview - Therapeutics Development - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview - Pipeline Products for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Comparative Analysis - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Development by Companies - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Products under Investigation by Universities/Institutes - Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Companies Involved in Therapeutics Development - Arrowhead Research Corporation - BioCryst Pharmaceuticals, Inc. - Cevec Pharmaceuticals GmbH - CSL Limited - Dyax Corp. - Global Blood Therapeutics, Inc. - iBio, Inc. - Isis Pharmaceuticals, Inc. - Pharming Group N.V. - ProMetic Life Sciences Inc. - Ra Pharmaceuticals, Inc. - Shire Plc For more information visit http://www.researchandmarkets.com/research/hfx77x/hereditary
GBT: 17.61 (-0.25), BCRX: 3.46 (+0.05), ISIS: 57.56 (-0.28), ARWR: 5.98 (-0.03), SHPG: 191.43 (-3.01), IBIO: 0.63 (unch), DYAX: 38.04 (-0.37)
Hemophilia A Therapeutics Pipeline Review 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rtzx4/hemophilia_a) has announced the addition of the "Hemophilia A - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Hemophilia A Overview - Therapeutics Development - Pipeline Products for Hemophilia A - Overview - Pipeline Products for Hemophilia A - Comparative Analysis - Hemophilia A - Therapeutics under Development by Companies - Hemophilia A - Therapeutics under Investigation by Universities/Institutes - Hemophilia A - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Hemophilia A - Products under Development by Companies - Hemophilia A - Products under Investigation by Universities/Institutes - Hemophilia A - Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - Apitope International NV - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - BioMarin Pharmaceutical Inc. - Catalyst Biosciences, Inc. - Celtic Pharmaceutical Holdings L.P. - CSL Limited - DBV Technologies S.A. - Dimension Therapeutics, Inc. - Dong-A Socio Group - Emergent BioSolutions Inc. - EpiVax, Inc. - Expression Therapeutics LLC - F. Hoffmann-La Roche Ltd. - Green Cross Corporation - Inbiopro Solutions Pvt. Ltd. - Lentigen Technology, Inc. - mAbxience S.A. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Selecta Biosciences, Inc. - SK Chemicals Co., Ltd. - Spark Therapeutics, Inc. - The International Biotechnology Center (IBC) Generium - uniQure N.V. For more information visit http://www.researchandmarkets.com/research/5r...mophilia_a
BMRN: 98.20 (+0.11), EBS: 32.85 (-0.93), PFE: 36.67 (-0.18), SGMO: 6.16 (-0.18), RBIO: (), DMTX: 7.26 (-0.18), NVO: 56.54 (+0.20), OPK: 9.89 (-0.06), ONCE: 55.39 (+1.40), AZN: 34.29 (+2.75), CBIO: 1.49 (unch), BXLT: 46.02 (-0.18)
Pharming Announces Completion of Patient Enrolment in Clinical Study of RUCONEST® for Prophylaxis of Hereditary Angioedema
PR Newswire Europe - Wed Jan 06, 12:01AM CST
LEIDEN, the Netherlands, January 6, 2016 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming awarded marketing authorisation in South Korea for RUCONEST for HAE
M2 - Mon Dec 21, 4:24AM CST
Medical company Pharming Group NV (Euronext Amsterdam
HARM) disclosed on Friday the receipt of the marketing authorisation for RUCONEST (recombinant human C1 inhibitor) in South Korea through its Seoul based South Korean specialty pharma partner, Hyupjin Corporation. Hemophilia B Therapeutics Pipeline Report H2 2015 - 19 Companies & 27 Drug Profiles
M2 - Tue Dec 15, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/2f4z4g/hemophilia_b) has announced the addition of the "Hemophilia B - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hemophilia B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia B and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alnylam Pharmaceuticals, Inc. - Amarna Therapeutics B.V. - AstraZeneca Plc - Baxalta Incorporated - Bayer AG - Biogen, Inc. - Catalyst Biosciences, Inc. - CSL Limited - Dimension Therapeutics, Inc. - Emergent BioSolutions Inc. - Novo Nordisk A/S - OPKO Health, Inc. - Pfizer Inc. - Pharming Group N.V. - RegenxBio Inc. - rEVO Biologics, Inc. - Sangamo BioSciences, Inc. - Spark Therapeutics, Inc. - uniQure N.V. Drug Profiles - albutrepenonacog alfa - ALN-AT3 - AMT-060 - AZ-10047130 - BAX-335 - BAY-1093884 - CB-2679d - CB-813d - Cell Therapy for Hemophilia B - coagulation factor IX (recombinant) - coagulation factor IX-Fc (recombinant), Fc fusion protein - coagulation factor VIIa (recombinant) - concizumab - CSL-689 - DTX-101 - Gene Therapy for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - Gene Therapy to Activate Factor IX for Hemophilia B - LR-769 - MOD-5014 - MOD-9017 - nonacog beta pegol - PF-06741086 - SB-FIX - SPK-FIX - SVF-VIIa For more information visit http://www.researchandmarkets.com/research/2f...mophilia_b
EBS: 32.85 (-0.93), PFE: 36.67 (-0.18), SGMO: 6.16 (-0.18), RBIO: (), DMTX: 7.26 (-0.18), NVO: 56.54 (+0.20), OPK: 9.89 (-0.06), ONCE: 55.39 (+1.40), AZN: 34.29 (+2.75), CBIO: 1.49 (unch), BXLT: 46.02 (-0.18)
Kidney Transplantation Therapeutics Pipeline Report 2015 - 25 Companies & 30 Drug Profiles
M2 - Mon Dec 14, 8:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqgdxr/kidney) has announced the addition of the "Kidney Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Kidney transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexion Pharmaceuticals, Inc. - Amyndas Pharmaceuticals LLC - Angion Biomedica Corp. - Astellas Pharma Inc. - Bio-inRen - Catalyst Biosciences, Inc. - CSL Limited - Digna Biotech, S.L. - Dompe Farmaceutici S.p.A. - Effimune SAS - GlaxoSmithKline Plc - Grifols, S.A. - Hansa Medical AB - Kyowa Hakko Kirin Co., Ltd. - Mabtech Limited - Novartis AG - Onyx Pharmaceuticals, Inc. - Opsona Therapeutics Limited - Pharming Group N.V. - Prolong Pharmaceuticals - Quark Pharmaceuticals, Inc. - Shire Plc - t-cell Europe GmbH - Tiziana Life Sciences Plc - Zyrnat Biotherapeutics SL Drug Profiles - albumin (human) - AMY-101 - AS-2521780 - basiliximab biobetter - BB-3 - belimumab - bleselumab - BRN-1889 - C1 esterase inhibitor (human) - Cardiotrophin-1 - carfilzomib - CB-2782 - Cell Therapy for Kidney Transplantation - CFZ-533 - Dendritic Cell Therapy for Multiple Sclerosis and Kidney Transplantation - eculizumab - EFFI-7H - ETR-002 - FCR-001 - foralumab - FR-104 - FX-06 - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - OPN-305 - QPI-1002 - Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - reparixin - Sanguinate - T-Cell Therapy for Kidney Transplant - ZY-11 For more information visit http://www.researchandmarkets.com/research/cqgdxr/kidney
SHPG: 191.43 (-3.01), CBIO: 1.49 (unch), ALXN: 130.40 (+0.62), GSK: 45.18 (+0.06), NVS: 82.08 (-0.81)
Fabry Disease Therapeutics Pipeline Review, H2 2015 - 12 Companies & 13 Drug Profiles
M2 - Thu Dec 03, 7:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/h8r98p/fabry_disease) has announced the addition of the "Fabry Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Fabry Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fabry Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Alexion Pharmaceuticals, Inc. - Amicus Therapeutics, Inc. - Biosidus S.A. - Genzyme Corporation - greenovation Biotech GmbH - iBio, Inc. - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Neuraltus Pharmaceuticals, Inc. - Pharming Group N.V. - Protalix BioTherapeutics, Inc. Drug Profiles - (migalastat hydrochloride agalsidase alfa) - agalsidase alfa - agalsidase beta biosimilar - Genz-682452 - GZ-402671 - lucerastat - migalastat hydrochloride - migalastat hydrochloride Enzyme Replacement Therapy Biobetter - MOSS-AGAL - NP-003 - PRX-102 - Recombinant Enzyme to Replace Alpha-Galactosidase A for Fabry's Disease - Recombinant Enzymes for Pompe, Fabry and Hunter Diseases For more information visit http://www.researchandmarkets.com/research/h8...ry_disease
ALXN: 130.40 (+0.62), IBIO: 0.63 (unch), FOLD: 6.80 (-0.33)
Pharming Reports on Extraordinary General Meeting of Shareholders
PR Newswire Europe - Wed Oct 28, 11:30AM CDT
LEIDEN, The Netherlands, October 28, 2015 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Pharming Group NV Interim Report January - September 2015
PR Newswire Europe - Wed Oct 28, 1:01AM CDT
LEIDEN, The Netherlands, October 28, 2015 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
FDA Grants RUCONEST® (C1 Esterase Inhibitor [Recombinant]) Twelve-Year Reference Product Exclusivity
PR Newswire Europe - Thu Oct 08, 12:01AM CDT
LEIDEN, Netherlands and BRIDGEWATER, New Jersey, October 8, 2015 /PRNewswire/ --
VRX: 23.13 (-0.36), VRX.TO: 30.45 (-0.51)
Global Gaucher's Disease Pipeline Review, H2 2015 - 16 Companies & 20 Drug Profiles
M2 - Wed Oct 07, 6:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hmwnzs/gauchers_disease) has announced the addition of the "Gaucher's Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gaucher's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gaucher's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Actelion Ltd - Amicus Therapeutics, Inc. - Bioorganic Research and Services S.A. - Biosidus S.A. - Dong-A Socio Group - Genzyme Corporation - greenovation Biotech GmbH - ISU ABXIS Co.,Ltd. - JCR Pharmaceuticals Co., Ltd. - Lixte Biotechnology Holdings, Inc. - Neuraltus Pharmaceuticals, Inc. - Okklo Life Sciences BV - Pharming Group N.V. - Protalix BioTherapeutics, Inc. - The International Biotechnology Center (IBC) Generium - UAB Profarma Drug Profiles - afegostat tartrate ERT - ambroxol - AT-3375 - BNT-001 - Gluco-Cerebosidase - GZ-402671 - imiglucerase biosimilar - LB-201 - LB-205 - miglustat - NP-003 - OKL-1014 - PRX-112 - Recombinant Enzyme to Replace Beta Glucosidase 2 for Gaucher's Disease and Male Infertility - Recombinant Enzyme to Replace Beta-Cerebrosidase for Gaucher's Disease - Small Molecule to Activate Beta-Galactosidase for GM1 Gangliosidosis and Gaucher's disease - Small Molecule to Activate Glucocerebrosidase for Parkinson's, Gaucher's and Neurodegenerative Diseases - Small Molecules to Activate Glucocerebrosidase for Gaucher and Parkinson Disease - Small Molecules to Inhibit Alpha-glucosidase for Diabetes and Gaucher's Disease - taliglucerase alfa For more information visit http://www.researchandmarkets.com/research/hm...rs_disease
FOLD: 6.80 (-0.33)
Pharming to elect Robin Wright as CFO at EGM
M2 - Tue Sep 08, 3:02AM CDT
Medical products company Pharming Group NV (Amsterdam
HARM.AS) reported on Tuesday that it plans to elect Robin Wright as its new chief financial officer (CFO) and member of the management board at an Extraordinary General Meeting (EGM) of shareholders to be held on 28 October 2015 at 14:00 CET. Ischemia Reperfusion Injury Pipeline Review, H1 2015 - 24 Companies & 63 Drug Profiles
M2 - Fri Jul 31, 9:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mw2sb6/ischemia) has announced the addition of the "Ischemia Reperfusion Injury - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Adienne Pharma & Biotech - Alligator Bioscience AB - Antipodean Pharmaceuticals, Inc. - BioLineRx, Ltd. - Biomedica Management Corporation - Bolder Biotechnology, Inc. - Catalyst Biosciences, Inc. - Curatis Pharma GmbH - Gilead Sciences, Inc. - Ischemix - LG Life Sciences, Ltd. - Lotus Pharmaceutical Co., Ltd. - Mercury Pharmaceuticals, Inc. - Omeros Corporation - Opsona Therapeutics Ltd. - Peptinnovate Limited - Pharming Group N.V. - PledPharma AB - Prolong Pharmaceuticals - Proteo, Inc. - Prothix BV - Trophos SA - Zealand Pharma A/S - Zyrnat Biotherapeutics SL Drug Profiles - ADC-1004 - AM/AMBP-1 - ANV-6L15 - APP-103 - BBT-030 - BBT-045 - BL-7060 - C1 esterase inhibitor (recombinant) - CB-2782 - CMX-2043 - CRX-526 - Curaglutide - danegaptide - Drugs to Inhibit ADAM17 for Ischemia Reperfusion Injury - Drugs to Modulate NKT II Cells for Autoimmune, Gastrointestinal and Cardiovascular Disorders - Elafin - EP-80317 - Ergidina - GS-459679 - KN-93 - KR-62980 - LSNTU-106 - mangafodipir - MFH-244 - MG-53 - mirococept - MitoQ - Monoclonal Antibody for Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation and Ischemia Reperfusion Injury - Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury - MTP-131 - NBD Peptide - NecX - Neutrolide - NOXD-21 For more information visit http://www.researchandmarkets.com/research/mw2sb6/ischemia
GILD: 81.24 (-0.55), OMER: 11.70 (+0.51)
